首页> 外文期刊>Plant Biotechnology Journal >Cold chain and virus-free chloroplast-made booster vaccine to confer immunity against different poliovirus serotypes
【24h】

Cold chain and virus-free chloroplast-made booster vaccine to confer immunity against different poliovirus serotypes

机译:冷链和无病毒叶绿体制成的增强疫苗,以赋予不同脊髓灰质炎病毒血清型的免疫力

获取原文
获取原文并翻译 | 示例
           

摘要

The WHO recommends complete withdrawal of oral polio vaccine (OPV) type 2 by April 2016 globally and replacing with at least one dose of inactivated poliovirus vaccine (IPV). However, high-cost, limited supply of IPV, persistent circulating vaccine-derived polioviruses transmission and need for subsequent boosters remain unresolved. To meet this critical need, a novel strategy of a low-cost cold chain-free plant-made viral protein 1 (VP1) subunit oral booster vaccine after single IPV dose is reported. Codon optimization of the VP1 gene enhanced expression by 50-fold in chloroplasts. Oral boosting of VP1 expressed in plant cells with plant-derived adjuvants after single priming with IPV significantly increased VP1-IgG1 and VP1-IgA titres when compared to lower IgG1 or negligible IgA titres with IPV injections. IgA plays a pivotal role in polio eradication because of its transmission through contaminated water or sewer systems. Neutralizing antibody titres (similar to 3.17-10.17 log(2) titre) and seropositivity (70-90%) against all three poliovirus Sabin serotypes were observed with two doses of IPV and plant-cell oral boosters but single dose of IPV resulted in poor neutralization. Lyophilized plant cells expressing VP1 stored at ambient temperature maintained efficacy and preserved antigen folding/assembly indefinitely, thereby eliminating cold chain currently required for all vaccines. Replacement of OPV with this booster vaccine and the next steps in clinical translation of FDA-approved antigens and adjuvants are discussed.
机译:谁建议在2016年4月全球和用至少一种剂量的灭活脊髓灰质病毒疫苗(IPV)替代口头脊髓灰质炎疫苗(OPV)2型型2型疫苗疫苗(OPV)。然而,高成本,IPV供应有限,持续的循环疫苗衍生的脊髓灰质病毒传输,并且需要随后的助推器仍未得到解决。为了满足这种关键需求,报道了单一IPV剂量之后的低成本冷链植物制造的病毒蛋白1(VP1)亚单位口服增强疫苗的新策略。密码子优化VP1基因的增强表达50倍的叶绿体。在与IPV的单引发后,在植物细胞中表达的植物细胞中的vp1的口服升压显着增加Vp1-IgG1和VP1-IgA滴度,与IPV注射的降低IgG1或可忽略的IgA滴度相比。由于其通过受污染的水或下水道系统的传输,Iga在脊髓灰质炎中发挥了关键作用。中和抗体滴度(类似于3.17-10.17 log(2)滴度)和血清病病毒Sabin血清型的血清阳性(70-90%)用两种剂量的IPV和植物细胞口服助推器观察到,但单剂量的IPV导致差中和。表达在环境温度下储存的VP1的冻干植物细胞无限期地保持功效并保存抗原折叠/组件,从而消除了所有疫苗所需的冷链。讨论了用这种增强疫苗替换OPV,并讨论了FDA批准的抗原和佐剂的临床翻译中的下一步。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号